Characteristics | HAIC-LEN-PD1 (n = 103) | LEN-PD1 (n = 61) | P |
---|---|---|---|
Gender Male Female | 91 (88.3%) 12 (11.7%) | 57 (93.4%) 4 (6.6%) | 0.288 |
Age, years (median, SD) | 52.0, 8.82 | 56.0, 7.88 | 0.115 |
ECOG score 0–1 2 | 96 (93.2%) 7 (6.8%) | 58 (95.1%) 3 (4.9%) | 0.627 |
BCLC B C | 4 (3.8%) 99 (96.2%) | 2 (3.3%) 59 (96.7%) | 0.842 |
Child-Pugh A B | 84 (81.6%) 19 (18.4%) | 50 (82.0%) 11 (18.0%) | 0.947 |
Viral status HBV others | 93 (90.3%) 10 (9.7%) | 58 (95.1%) 3 (4.9%) | 0.272 |
Tumor size, cm (Mean) ≥ 10 cm < 10 cm | 71 (68.9%) 32 (31.1%) | 45 (73.8%) 16 (26.2%) | 0.510 |
Portal vein invasion Absent VP1-2 VP3 VP4 | 9 (8.7%) 5 (4.9%) 19 (18.4%) 70 (68.0%) | 4 (6.6%) 5 (8.2%) 9 (14.8%) 43 (70.4%) | 0.882 |
Venous invasion Absent Present | 76 (73.8%) 27 (26.2%) | 50 (82%) 11 (18%) | 0.230 |
Extrahepatic spread Absent Present | 71 (68.9%) 32 (31.1%) | 41 (67.2%) 20 (32.8%) | 0.819 |
Tumor number Single Multiple | 39 (37.9%) 64 (62.1%) | 25 (41%) 36 (59%) | 0.692 |
AFP, ng/ml(Mean) ≤ 400 > 400 | 33 (32.0%) 70 (68.0%) | 26 (42.6%) 35 (57.4%) | 0.172 |
High-risk type VP4 TO 50% Both | 54 (52.4%) 33 (32.1%) 16 (15.5%) | 31 (50.8%) 18 (29.5%) 12 (19.7%) | 0.802 |
PD-1 inhibition agent Camrelizumab Tislelizumab Sintilimab | 62 (60.2%) 26 (25.2%) 15 (14.6%) | 32 (52.5%) 20 (32.8%) 9 (14.7%) | 0.694 |
ALBI grade I II III | 54 (52.4%) 47 (45.7%) 2 (1.9%) | 25 (41.0%) 33 (54.1%) 3 (4.9%) | 0.257 |
Laboratory tests TBil, µmol/L (Mean, SD) Albumin, g/L (Mean, SD) Platelet, ×109/L (Mean, SD) WBC, ×109/L (Mean, SD) PT, seconds (Mean, SD) Creatinine, µmol/L (Mean, SD) ALT, IU/L (Mean, SD) AST, IU/L (Mean, SD) | 21.4, 12.3 38.4, 4.2 180.6, 78.6 6.0, 1.8 12.1, 1.1 65.5, 12.4 89.4, 55.9 58.1, 39.9 | 23.4, 14.4 39.3, 6.6 192.9, 86.6 6.4, 2.8 12.1, 1.1 75.0, 85.7 77.7, 38.6 49.9, 28.4 | 0.473 0.440 0.479 0.469 0.991 0.340 0.713 0.603 |